Literature DB >> 28213589

SH479, a Betulinic Acid Derivative, Ameliorates Experimental Autoimmune Encephalomyelitis by Regulating the T Helper 17/Regulatory T Cell Balance.

Jing Li1, Ji Jing1, Yang Bai1, Zhen Li1, Roumei Xing1, Binhe Tan1, Xueyun Ma1, Wen-Wei Qiu1, Changsheng Du1, Bing Du1, Fan Yang1, Jie Tang1, Stefan Siwko1, Mingyao Liu2, Huaqing Chen2, Jian Luo2.   

Abstract

CD4+ T helper cells, especially T helper 17 (TH17) cells, combined with immune regulatory network dysfunction, play key roles in autoimmune diseases including multiple sclerosis (MS). Betulinic acid (BA), a natural pentacyclic triterpenoid, has been reported to be involved in anti-inflammation, in particular having an inhibitory effect on proinflammatory cytokine interleukin 17 (IL-17) and interferon-γ (IFN-γ) production. In this study, we screened BA derivatives and found a BA derivative, SH479, that had a greater inhibitory effect on TH17 differentiation. Our further analysis showed that SH479 had a greater inhibitory effect on TH17 and TH1, and a more stimulatory effect on regulatory T (Treg) cells. To evaluate the effects of SH479 on autoimmune diseases in vivo, we employed the extensively used MS mouse model experimental autoimmune encephalomyelitis (EAE). Our results showed that SH479 ameliorated clinical and histologic signs of EAE in both prevention and therapeutic protocols by regulating the TH17/Treg balance. SH479 dose-dependently reduced splenic lymphocyte proinflammatory factors and increased anti-inflammatory factors. Moreover, SH479 specifically inhibited splenic lymphocyte viability from EAE mice but not normal splenic lymphocyte viability. At the molecular level, SH479 inhibited TH17 differentiation by regulating signal transducer and activator of transcription-3 (STAT3) phosphorylation, DNA binding activity, and recruitment to the Il-17a promoter in CD4+ T cells. Furthermore, SH479 promoted the STAT5 signaling pathway and inhibited the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway. Together, our data demonstrated that SH479 ameliorated EAE by regulating the TH17/Treg balance through inhibiting the STAT3 and NF-κB pathways while activating the STAT5 pathway, suggesting that SH479 is a potential novel drug candidate for autoimmune diseases including MS.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28213589     DOI: 10.1124/mol.116.107136

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  3 in total

1.  A Betulinic Acid Derivative, BA5, Induces G0/G1 Cell Arrest, Apoptosis Like-Death, and Morphological Alterations in Leishmania sp.

Authors:  Tatiana Barbosa Dos Santos Magalhães; Dahara Keyse Carvalho Silva; Jessica da Silva Teixeira; Juliana Dizaira Teles De Lima; José Maria Barbosa-Filho; Diogo Rodrigo Magalhães Moreira; Elisalva Teixeira Guimarães; Milena Botelho Pereira Soares
Journal:  Front Pharmacol       Date:  2022-03-22       Impact factor: 5.810

Review 2.  Semisynthetic Derivatives of Pentacyclic Triterpenes Bearing Heterocyclic Moieties with Therapeutic Potential.

Authors:  Gabriela Nistor; Cristina Trandafirescu; Alexandra Prodea; Andreea Milan; Andreea Cristea; Roxana Ghiulai; Roxana Racoviceanu; Alexandra Mioc; Marius Mioc; Viviana Ivan; Codruța Șoica
Journal:  Molecules       Date:  2022-10-03       Impact factor: 4.927

3.  CD4+T cell specific B7-H1 selectively inhibits proliferation of naïve T cells and Th17 differentiation in experimental autoimmune encephalomyelitis.

Authors:  Sheng-Jia Shi; Mei-Ling Ding; Li-Juan Wang; Jie-Heng Wu; Dong-Hui Han; Guo-Xu Zheng; Zhang-Yan Guo; Wen-Jin Xi; Wei-Jun Qin; An-Gang Yang; Wei-Hong Wen
Journal:  Oncotarget       Date:  2017-09-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.